Lung Cancer Survivor and Wife to Run Kiawah Half Marathon For the average person, running 13.1 miles can sound like a daunting task. Now imagine running that distance while battling lung cancer! That is just what lung cancer survivor Rob Youth and his wife Amanda plan to do on Saturday,
Press Release FOR IMMEDIATE RELEASE ON NOVEMBER 15, 2016 Contact: Heather Hooper Executive Director Lung Cancer Initiative of North Carolina (919) 784-0410 HHooper@LungCancerInitiativeNC.org Hope for Leading Cause of Cancer Related Deaths November 15, 2016 (Raleigh, NC) – It can be
On May 8, 2014 upon completion of four cycles of adjuvant chemotherapy with Cisplatin/Alimta I received the verdict: I WAS IN REMISSION. My original diagnosis was stage II adenocarcinoma of the lung. It was my upper left lobe. I had surgery to remove the tumor in December of 2013. I had 10
“We received the results of your biopsy on that lymph node, Mrs. Hargraves. Would you like to come into the office?” Thus, with that phone call from my primary care physician, my journey with lung cancer began. After a CT scan later that day, I was officially diagnosed with stage 3B, non-small
Click here to read original article from Triangle Business Journal by Jennifer Henderson. The Lung Cancer Initiative of North Carolina and The V Foundation for Cancer Research have partnered to fund new research focused on lung cancer among the African-American population in the state. The
Contact: Heather Hooper 919-784-0410 hhooper@LungCancerInitiativeNC.org Margaret Pentrack 412-337-2997 FOR IMMEDIATE RELEASE Lung Cancer Initiative and The V Foundation Expand Partnership to Fund Lung Cancer Research Grant Recipients Will Research Disparities Among
The Lung Cancer Initiative of North Carolina is pleased to announce Cancer Services and Community Health Coalition as the recipients of 5,000 Access Grants each. The goal of the Access Grant Program is to partner with community organizations in North Carolina to improve access to care and
FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR GENENTECH’S ALECENSA® (ALECTINIB) FOR FIRST-LINE TREATMENT OF PEOPLE WITH ALK-POSITIVE NSCLC – This Second Alecensa Breakthrough Therapy Designation Was Granted Based on Phase III J-ALEX Study – SOUTH SAN FRANCISCO, Calif. – October 3, 2016
The other day I was in Lowe’s looking for light bulbs and an elderly man was wearing a hat with the ship he served on just like the one my grandfather wore daily. The emotions caught me off guard. I will miss seeing my grandfather or ‘Old Man’ wearing a similar hat. My grandfather served over 20
Press Release FOR IMMEDIATE RELEASE ON SEPTEMBER 14, 2016 Contact: Cynamon Frierson Communications & Marketing Manager Lung Cancer Initiative of North Carolina (919) 669-9531 cfrierson@lungcancerinitiativenc.org 10th Annual Raleigh LUNGe Forward 5K Run, Walk & Rally September 14,
© 2018 Lung Cancer Initiative of North Carolina, All Rights Reserved. | Privacy Policy | Site Map
